Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Morphic Holding Inc
(NQ:
MORF
)
56.99
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphic Holding Inc
< Previous
1
2
3
4
5
Next >
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
October 09, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
September 29, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
September 29, 2023
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.
Via
Investor's Business Daily
Where Morphic Holding Stands With Analysts
September 28, 2023
Via
Benzinga
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
July 17, 2023
Via
Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
June 05, 2023
Via
Investor Brand Network
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
September 26, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Gold Moves Lower; TransCode Therapeutics Shares Surge
September 25, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
September 25, 2023
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 25, 2023
Via
Benzinga
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10
May 10, 2023
Via
Investor Brand Network
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
September 25, 2023
The company is working on a treatment for ulcerative colitis. But competitive questions linger.
Via
Investor's Business Daily
Nasdaq Turns Higher; SCYNEXIS Shares Plunge
September 25, 2023
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
September 25, 2023
Via
Benzinga
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
September 22, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 22, 2023
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 22, 2023
Via
Benzinga
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 09, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
August 09, 2023
Via
Benzinga
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
June 08, 2023
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist.
Via
InvestorPlace
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
May 11, 2023
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 05, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
More Than $47M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
May 05, 2023
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
May 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.